Article
Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.
Molecular oncology - 1 Oct 2016
Denis Jérôme Alexandre, Patroni Alexia, Guillerm Erell, Pépin Dominique, Benali-Furet Naoual, Wechsler Janine, Manceau Gilles, Bernard Maguy, Coulet Florence, Larsen Annette K, Karoui Mehdi, Lacorte Jean-Marc
Abstract excerpt
In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR-targeted antibodies cetuximab and panitumumab. Since it can be difficult to obtain appropriate tumor tissues for KRAS genotyping, alternative methods are required. Circulating tumor cells (CTCs) are believed to be representative of the tumor in real time. In this study we explored the capacity of a size-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.